Albireo Pharma (NASDAQ:ALBO) is scheduled to announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.37) per share for the quarter.

Albireo Pharma (NASDAQ:ALBO) last announced its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.18). Albireo Pharma had a negative net margin of 361.94% and a negative return on equity of 32.42%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $1.94 million. On average, analysts expect Albireo Pharma to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of NASDAQ:ALBO opened at $35.30 on Friday. Albireo Pharma has a one year low of $19.10 and a one year high of $37.95. The stock has a market capitalization of $424.98 million, a PE ratio of -8.96 and a beta of 1.72.

Several research analysts recently issued reports on the stock. BidaskClub raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Friday. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, April 1st. Cowen reissued a “buy” rating on shares of Albireo Pharma in a report on Wednesday, April 17th. Zacks Investment Research cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, March 11th. Finally, Wedbush set a $69.00 price target on shares of Albireo Pharma and gave the stock a “buy” rating in a report on Sunday, March 10th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating to the company. Albireo Pharma has a consensus rating of “Buy” and an average target price of $54.25.

An institutional investor recently raised its position in Albireo Pharma stock. Geode Capital Management LLC increased its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 11.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,434 shares of the biopharmaceutical company’s stock after purchasing an additional 9,922 shares during the period. Geode Capital Management LLC owned approximately 0.81% of Albireo Pharma worth $2,390,000 as of its most recent SEC filing. 66.94% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Albireo Pharma (ALBO) Set to Announce Earnings on Thursday” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Balance Sheet

Earnings History for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.